Plain-English translation of NCT05797168 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new cancer drug called AZD5335 (also known as Torvu-sam) to see if it can help people with advanced solid tumors like ovarian, lung, and endometrial cancer. The medication will be tested in different ways — some people will take it alone, while others will take it combined with other established cancer treatments. Researchers want to learn if the medication is safe, how the body handles it, and whether it helps shrink tumors.
Current cancer treatments don't work for everyone, and some people develop resistance or experience side effects. This trial aims to explore whether this new medication might offer another option, either by itself or by enhancing the effects of other anti-cancer drugs already used in clinical practice.
You likely qualify if…
You likely don't qualify if…
You will visit a clinic regularly to receive the medication — either as a pill or infusion, depending on which group you join — and have blood tests and scans to monitor how you respond and check for side effects. Some participants will receive the medication alone, while others will receive it combined with one or more established anti-cancer drugs. The study will track you over weeks and months to see if the treatment is working and is safe for you.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
United States